Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study

Table 3 Univariate risk factor analysis in total knee arthroplasty patients for excessive bleeding and transfusions

	Excessive bleeding (EBL/ kg > 12.7 mL/ kg)			Allogeneic RBC transfusion
	OR	95% CI	p value	OR	95% CI	p value
Age (years)	1.02	0.97–1.08	0.45	0.99	0.92–1.06	0.79
Sex (F)	0.69	0.24–1.95	0.49	0.29	0.068–1.28	0.10
BMI (kg/ m ² )	0.81	0.69–0.95	0.010	0.78	0.62–0.98	0.034
Weight (kg)	0.96	0.92–1.0	0.046	0.97	0.92–1.02	0.26
NSAID (No)	0.94	0.26–3.34	0.92	0.88	0.16–4.68	0.88
ASA (No)	1.14	0.32–4.0	0.84	2.57	0.3–22.02	0.39
SSRI (No)	1.12	0.21–5.93	0.89	1.03	0.11–9.37	0.98
Hemoglobin (g/ L)	1.09	1.03–1.16	0.001	0.91	0.84–0.97	0.007
Platelet count (10 ⁹ /L)	1.0	0.99–1.01	0.56	1.001	0.99–1.01	0.88
PT (INR)	0.001	0.00–1.03	0.051	0.036	0–220.4	0.46
aPTT (s)	0.91	0.78–1.07	0.26	1.34	1.03–1.74	0.028
Operation time (minutes)	1.00	0.98–1.02	0.87	1.03	1.00–1.06	0.034
Anesthesia (spinal)	2.12	0.43–10.48	0.35	0.72	0.13–3.92	0.71
EBL/ kg		n.a.		1.020	0.88–1.18	0.795

Abbreviations: aPTT activated partial thromboplastin time, ASA acetyl salicylic acid, BMI body mass index, EBL estimated blood loss, LMWH low molecular weight heparin, NSAID nonsteroidal anti-inflammatory drugs, PT prothrombine time, RBC transfusion red blood cell transfusion, SSRI selective seretonine receptor inhibitor.

ISSN: 1749-799X